Overall my thoughts, AMRN very well prepared, FDA fumbling, FDA believes M.O. is not an issue and is off the table. 2 Adcom members , one conflicted and one have statistical issues seem to have problems with data. Hopefully AMRN will get a change to follow back up with answers the FDA could not answer in that last "clarifying questions" section.
News 
Market Data 
Discover 
AI
